Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 20, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their holdings of Ordinary shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to specific transaction prices:
- Ordinary Share Purchase Price: £11.22 per share
- ADR Purchase Price: $33.85 per ADR
Material Changes
The filing details an increase in shareholdings for multiple executives and directors on October 15, 2008. These transactions resulted from the re-investment of dividends paid to shareholders on October 9, 2008. No material changes to the company's operations or financial position are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is strictly a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of shares and ADRs acquired by each named executive to assess the scale of their re-investment.
- Confirm the dividend payment date of October 9, 2008, to understand the timing of the re-investment.
- Note that this filing does not reflect the company's overall financial performance for the period; refer to Form 20-F for comprehensive financial data.